FDA 483 - Hetero Drugs Ltd. - Unit 1
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Hetero Drugs Limited, an API drug manufacturer, revealed significant deficiencies in laboratory control testing for Active Pharmaceutical Ingredients. The firm was found to have inhibited integration of HPLC peaks during related substance testing, which could mask impurities, and lacked adequate Standard Operating Procedures for chromatographic practices. These issues indicate a failure to ensure accurate and reliable data for drug products marketed in the United States.
- Company
- Hetero Drugs Ltd. - Unit 1
- Product Type
- Drugs
ID · 2f5e8642-953a-44f2-b954-3649b3a9f37d